Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-17T19:36:24.042Z Has data issue: false hasContentIssue false
  • English
  • Français

The Treatment of Narcolepsy-Cataplexy with Nocturnal Gamma-Hydroxybutyrate

Published online by Cambridge University Press:  18 September 2015

Roger Broughton  and
Mortimer Mamelak
Roger Broughton*
Affiliation:
Division of Neurology, Ottawa General Hospital and University of Ottawa and the Department of Psychiatry, Sunnybrook Medical Centre and University of Toronto, Canada
Mortimer Mamelak
Affiliation:
Division of Neurology, Ottawa General Hospital and University of Ottawa and the Department of Psychiatry, Sunnybrook Medical Centre and University of Toronto, Canada
*
Department ot Medicine (Neurology), Ottawa General Hospital, Ottawa, Canada, ?1N 5C8.
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Sixteen patients with narcolepsy and cataplexy were treated with gamma-hydroxybutyrate (GHB) given at night and tailored to achieve as continuous a night's sleep as possible. The dosage usually consisted of 1.5-2.25 gm orally at bedtime and then one or two further 1.0-1.5 gm doses with awakenings during the night, and totaled about 50 mg /kg. Apart from one patient who took only the bedtime dose, the subjective quality of night sleep improved in all patients and the number of irresistable daytime attacks of sleep and cataplexy substantially diminished. Some residual daytime drowsiness remained and this usually responded well to low doses of methylphenidate. Improvement has been maintained for up to 20 months without the development of tolerance. Two patients experienced adverse side effects necessitating withdrawal of GHB treatment, but no serious toxic effects have occurred.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 6 , Issue 1 , February 1979 , pp. 1 - 6
Copyright
Copyright © Canadian Neurological Sciences Federation 1979

References

Broughton, R. (1971). Neurology and sleep research. Can. Psychiatr. Assoc. J., 16, 283–292.CrossRefGoogle ScholarPubMed
Broughton, R. and Ghanem, Q. (1976). A study of the. impact of compound narcolepsy on the life of the patient. In Narcolepsy, edited by Guilleminault, C., Dement, W. C. and Passouant, P., pp. 201–220. Spectrum: New York.Google Scholar
Broughton, R. and Mamelak, M. (1976). Gamma-hydroxybutyrate in the treatment of compound narcolepsy: A preliminary report. In Narcolepsy, edited by Guilleminault, C., Dement, W. C. and Passouant, P., pp. 659–667. Spectrum: New York.Google Scholar
Cordeau, J. P. (1970). Monoammes in the physiology of sleep and waking. In L-Dopa and Parkinsonism, edited by Barbeau, A. and McDowell, F. H., pp. 369–383. Davis: Philadelphia.Google Scholar
Daly, D. D. and Yoss, R. E. (1960). Narcolepsy. Med. Clin. North Am., 44, 953–968.Google Scholar
Daniels, L. (1934). Narcolepsy. Medicine (Baltimore), 13, 1–22.CrossRefGoogle Scholar
De La Mora, M. and Tapia, R. (1970). Neurochemical and physiological aspects of gamma-hydroxy-butyric acid as a natural soporific. Ann. Instit. Boil. Auton. Mex., 1, 41–53.Google Scholar
Dement, W. C., Carskadon, M. A., Guilleminault, C., and Zarcone, V. P. (1976). Narcolepsy: diagnosis and treatment. Primary Care, 3, 609–623.CrossRefGoogle ScholarPubMed
Dement, W. C., Carskadon, M. and Ley, R. (1973). The prevalence of narcolepsy, II. Sleep Research, 2, 147.Google Scholar
Doherty, J. D. and Roth, R. H. (1976). Identification of gamma-hydroxybutyric acid as an endogenous metabolite present in monkey and human brain. Fed. Proc, 35, 270.Google Scholar
Helrich, M., McAslan, T.C., Skolnik, S., Bessman, S. P. (1964). Correlation of blood levels of 4-hydroxybutyrate with state of consciousness. Anaethesiology. 25, 771–775.CrossRefGoogle ScholarPubMed
Hiskikawa, Y., Wakamatsu, H., Furuya, E., Sugita, Y., Masaoka, S., Kaneda, H., SATO, M., Nan'no, H., and Kaneko, Z. (1976). Sleep satiation in narcoleptic patients. Electroencephalogr. Clin. Neurophysiol., 41, 1–18.CrossRefGoogle Scholar
Hoddes, E., Zarcone, V., Smythe, H., Phillip, S., and Dement, W. (1973). Quantification of sleepiness: A new approach. Psychophysiology, 10, 431–436.CrossRefGoogle ScholarPubMed
Jasper, H. and Koyama, I. (1969). Rate of release of amino acids from cerebral cortex in the cat as affected by brainstem and thalamic stimulation. Can. J. Physiol. Pharmacol., 47, 889–905.CrossRefGoogle ScholarPubMed
Jouvet, M. (1969). Biogenic amines and the states of sleep. Science, 163, 32–41.CrossRefGoogle ScholarPubMed
Jouvet, M., Cier, A., Mounier, D., Valatx, J. L. (1961). Effets du 4-butyrolactone et du 4-hydroxybutyrate de sodium sur l'EEG et le comportement du chat. C. R. Soc. Biol. (Paris), 155, 1313–1316.Google Scholar
Laborit, H. (1964). Sodium-4-hydroxybuty-rate. Int. J. Neuropharmacol., 3, 433–451.CrossRefGoogle Scholar
Mamblak, M., Escriu, J. M. and Stokan, O. (1977). The effects of gamma-hydroxybutyrate on sleep. Biol. Psychiatry, 12, 273–288.Google Scholar
Matsuzaki, M., Takagi, H. and Tokizane, T. (1964). Paradoxical phase of sleep: Its artificial induction in the cat by sodium butyrate. Science, 146, 1328–1329.CrossRefGoogle ScholarPubMed
Mitchell, S. A. and Dement, W. C. (1968). Narcolepsy syndromes: antecedent, contiguous and concomitant nocturnal sleep disordering and deprivation. Psychophysiology, 4, 398.Google Scholar
Montplaisir, J. (1976). Disturbed nocturnal sleep. In Narcolepsy, edited by Guilleminault, C., Dement, W. C. and Passouant, P., pp. 43–56. Spectrum: New York.Google Scholar
Morgane, P. J. and Stern, W. C. (1972). Relationship of sleep to neuroanatomical circuits biochemistry, and behavior. Ann. N.Y. Acad. Sci., 193, 95–111.CrossRefGoogle ScholarPubMed
Muzard, J. P. and Laborit, H. (1977). Gammahydroxybutyrate. In Psychothera-peutic Drugs, Part II, edited by Usdinand, E. I. Forrest. Marcel Dekker: New York.Google Scholar
Rechtschaffen, A., Wolpert, E., Dement, W., Mitchell, S. and Fisher, C. (1963). Nocturnal sleep of narcoleptics. Electroencephalogr. Clin. Neurophysiol., 15, 599–609.CrossRefGoogle ScholarPubMed
Roth, B. (1962). Narcolepsie und Hypersomnie.V.E.B. Verlag Volk und Gesundheit: Berlin, p. 428.Google Scholar
Roth, R. H. and Giarman, N. J. (1969). Conversion in vivo of gamma-aminobutyric to gamma-hydroxybutyric acid in the rat. Biochem. Pharmacol., 18, 147–250.CrossRefGoogle ScholarPubMed
Roth, R. H. and Suhr, Y. (1970). Mechanism of the gamma-hydroxybutyrate induced increase in brain dopamine and its relationships to “sleep”. Biochem. Pharmacol., 19, 3001, 3012.Google Scholar
Roth, R. H., Nowycky, M. C., Walters, J. R. and Morgenroth, V. H. (1977). Gammahydroxybutyrate: Effects on Nonstriated Dopaminergic Neurons. Adv. Biochem. Psychopharmacol., 16, 483–488.Google Scholar
Snead, O. C. (1977). Gammahydroxybutyrate. Life Sci., 20, 1935–1944.CrossRefGoogle Scholar
Spano, P., Neff, N. and Costa, E. (1970). Effect of gammahydroxybutyrate on the synthesis rate of brain amines. Trans. Am. Soc. Neurochem., 1, 69.Google Scholar
Uspenskii, A. E. (1965). Effect of sodiumsalt of gamma-hydroxybutyric acid on synaptic transmission in the spinal cord. Fed. Proc., 24, 673–675.Google Scholar
Vickers, M.D. (1969). Gamma-hydroxybutyric acid. Int. Anaesthesiol. Clin., 7, 75–89.CrossRefGoogle Scholar
Yamada, Y., Yamamoto, J., Fujiki, A., Hishikawa, Y. and Kanedo, Z. (1967). Effect of butyrolactone and gammahydroxybutyrate in the EEG and sleep cycle in man. Electroencephalogr. Clin. Neuro-physio., 22, 558–562.Google Scholar
Zarcone, V. (1973). Narcolepsy. N. Engl. J. Med., 288, 1156–1166.CrossRefGoogle ScholarPubMed